

2023 Blue Cross Blue Shield of Michigan Cardiovascular Consortium
 Collaborative Quality Initiative Performance Index Scorecard
PCI & VS Combined - #1
 (VS sites with EVAR and CEA volumes >=10 cases per year)
 Participation Measurement Period: 01/01/2023 - 12/31/2023
 Performance Measurement Period: 01/01/2023 - 9/30/2023

Measure #	Weight	Measure Description	PCI Points	VS Points
1	10	Meeting Participation - Clinician Lead		
		2 Meetings	5	5
		1 Meeting	2.5	2.5
		Did not participate	0	0
2	7.5	Data Coordinator Expectations		
		Meets all expectations	3.75	3.75
		Meets most expectations	2.5	2.5
		Does not meet expectations	0	0
3	2.5	Internal Case Reviews		
		Submitted reviews for ≥90% of cases	2.5	NA
		Submitted reviews for <90% of cases	0	NA
4	10	Physicians Complete Cross Site Review of Assigned Cases for Procedural Indications and Technical Quality		
		Submitted reviews for 100% of cases	5	5
		Submitted reviews for <100% of cases	0	0
5	12.5	Vascular Surgery Performance Goal - Completion of 1-year follow up forms		
		≥80%	NA	12.5
		70% - <80%	NA	7.5
		<70%	NA	0
6	(10)	Vascular Surgery Performance Goal - Documentation of EVAR† imaging performed on the 1-year follow up form		
		≥70%	NA	10
		60% - <70%	NA	5
		<60%	NA	0
7	(10)	Vascular Surgery Performance Goal – Surgeons to prescribe a maximum of 4 opioid pills for opioid naïve patients with EVAR† at discharge		
		≥70%	NA	10
		60% - <70%	NA	5
		<60%	NA	0
8	(10)	Vascular Surgery Performance Goal – Surgeons to prescribe a maximum of 4 opioid pills for opioid naïve patients with CEA* at discharge		
		≥70%	NA	10
		60% - <70%	NA	5
		<60%	NA	0
Sites select two measures for scoring from measures 6, 7, and 8.				
9	12.5	PCI Performance Goal - Documentation of recommended P2Y12 therapy duration		
		≥75%, or a ≥20 percentage points absolute increase from Q4 YTD 2022	12.5	NA
		65% - <75%	7.5	NA
		<65%	0	NA
10	12.5	PCI Performance Goal - Pre PCI hydration (oral and/or IV) (volume/3ML/Kg) in patients with eGFR** < 60 (excludes dialysis, cardiac arrest, cardiogenic shock, PCI status of "salvage" and symptomatic heart failure NYHA^^ 2,3,4, and STEMI††).		
		≥70%, or a ≥10 percentage points absolute increase from Q4 YTD 2022	12.5	NA
		60% - <70%	7.5	NA
		<60%	0	NA
11	12.5	PCI Performance Goal - Use of IVUS/OCT * for stent optimization		
		≥40% in EITHER all cases OR ≥40% in cases involving the left main coronary artery, in-stent restenosis, or stent thrombosis	12.5	NA
		≥20 percentage points absolute increase in all cases from Q4 YTD 2022	10	NA
		10 - <20 percentage points absolute increase in all cases from Q4 YTD 2022	7.5	NA
		<10 percentage points absolute increase in all cases from Q4 YTD 2022	0	NA

**eGFR=estimated glomerular filtration rate

^^NYHA= New York Heart Association heart failure class

††STEMI=ST elevated myocardial infarction

†EVAR=endovascular aortic aneurysm repair

*CEA=carotid endarterectomy

* IVUS/OCT=intra-vascular ultrasound/optical coherence tomography

Indicates Participation Measures

Indicates Performance Measures